In the 2022/2023 business year, the company’s product portfolio consisted of 653 products

Egis: Committed to Support Healthcare Workers

Egis Pharmaceutical PLC is committed to support the safety of medical staff in the current pandemic situation.


The continuous operation of Egis is vital

The quality of life of millions depends on the availability of our medicines, as Egis sells the most boxes of medicine in Hungary. Hungarian doctors most often choose Egis medicines particularly for the therapy of cardiovascular diseases, which is a common disease. Our medicines provide therapeutic solutions for the diseases cardiovascular diseases (38%), for the illnesses of the central nervous system (17%) and respiratory system (10%), further 10% are cancer treatment and immunotherapeutic drugs. Taking these medicines continuously is essential for maintaining the patients’ quality of life and for the success of the therapy.


Wash Your Hands the Right Way

WHO has created a six-step protocol: by applying this method, we can remove the germs, viruses, and bacteria from the surface of our hands.


Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox